Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer A Retrospective Matched Case-Control Study

Hamzeh Kayhanian, Emily Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David Gonzalez de Castro, Scott Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)



Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group.


All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified. BRAF-MT mCRC cases were compared with an age and sex-matched BRAF-WT control group. Clinicopathological data were collected and survival calculated using the Kaplan-Meier method and comparisons made using Cox regression.


Forty-three of 503 patients (8.5%) tested had BRAF-MT mCRC and were compared with 88 BRAF-WT controls. Median overall survival (mOS) was 18.2 months for BRAF-MT and 41.1 months for BRAF-WT mCRC patients (hazard ratio, 2.74; 95% confidence interval, 1.60-4.70; P < .001). Progression-free survival for BRAF-MT and WT patients, respectively, was: 8.1 months versus 9.2 months (P = .571) first-line, 5.5 months versus 8.3 months (P = .074) second-line, and 1.8 months versus 5.6 months (P = .074) third-line. Treatment using sequential fluoropyrimidine-based doublet chemotherapy was similar between both groups. Anti-epidermal growth factor receptor (EGFR) therapy was mainly given third-line with progressive disease in 90% (n = 9 of 10) of BRAF-MT patients at first restaging.


In this case-control study, the poor mOS of BRAF-MT mCRC was associated with reduced treatment benefit beyond first-line. Sequential doublet chemotherapy remains a reasonable option in appropriately selected patients. BRAF-MT patients did not benefit from anti-EGFR therapy in this study. Recruitment to clinical trials is recommended to improve outcomes in BRAF-MT mCRC.

Original languageEnglish
JournalClinical colorectal cancer
Issue number1
Early online date16 Oct 2017
Publication statusPublished - Mar 2018


  • Journal Article


Dive into the research topics of 'Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer A Retrospective Matched Case-Control Study'. Together they form a unique fingerprint.

Cite this